THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTES AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Curis

Scan this QR code to view Prospectus

CURIS LIFESCIENCES LIMITED

CIN: U24230GJ2016PLC086559

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceuticals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation dated March 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/Deputy Registrar of Companies/Registrar of Companies, Central Processing Centre.

Registered Office: PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat -382110, India.
Company Secretary and Compliance Officer: Mr. Nikhil Purohit
Website: https://curisls.com/ **E-Mail:** cs@curisls.com **Telephone No:** +91 99045 22543

PROMOTERS OF OUR COMPANY: MR. DHARMESH DASHARATHBHAI PATEL, MR. SIDDHANT JAYANTIBHAI PAWASIA, MR. PIYUSH GORDHANBHAI ANTALA AND MR. JAIMIK MANSUKHLAL PATEL

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE ("NSE EMERGE")."

Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments. We are in business of manufacturing of pharmaceutical products.

For further details, please see chapter titled "Business Overview" beginning on page 133 of the Prospectus.

BASIS OF ALLOTMENT CUM CORRIGENDUM

INITIAL PUBLIC ISSUE OF 21,50,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF CURIS LIFESCIENCES LIMITED ("CURIS" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 2752.00 LAKHS ("THE ISSUE"), OF WHICH 1,08,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE AGGREGATING TO ₹ 138.24 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 20,42,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE AGGREGATING TO ₹ 2613.76 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.59 % AND 25.26 %, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10 EACH AND ISSUE PRICE IS ₹ 128 EACH
THE ISSUE PRICE IS 12.80 TIMES OF THE FACE VALUE OF THE EQUITY SHARE.
ANCHOR INVESTOR ISSUE PRICE: ₹ 128 PER EQUITY SHARE. THE ISSUE PRICE IS 12.80 TIMES OF THE FACE VALUE.

BID/ ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: NOVEMBER 6, 2025, THURSDAY
BID/ISSUE OPENED ON: NOVEMBER 7, 2025, FRIDAY
BID/ISSUE CLOSED ON: NOVEMBER 11, 2025, TUESDAY

RISKS TO INVESTORS

Summary description of key risk factors based on materiality

1. Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
2. As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
3. Our business operations are subject to fluctuations in raw material prices.
4. Any non-compliance or delays in Instalments of Outstanding loan may expose us to penalties from the Bank.
5. The company relies on a limited number of customers for its sales, and the loss of any major customer could adversely impact our revenue and profitability.
6. The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.
7. We depend on a limited number of States for a significant portion of our revenue from operations. The loss of any of our major customer in these States due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
8. Our Company is dependent on few countries. Loss of any of these large countries may affect our business operations.
9. A disclosure remark on compliance of Companies (Auditor's Report) Order, 2020 towards non payment of statutory dues in financial year ended March 31, 2020, March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024 have been noted by our Statutory Auditors in their reports.
10. Our Company depends on some of our Products which contributes more than 90% of the total revenue of the company. The loss of any of this major Products due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.

For details refer to chapter titled "Risk Factors" beginning on page 25 of the Prospectus.

1. **The Average Cost of acquisition of Equity Shares held by our Promoters is as follows:**

Sr. No.	Name	No. of Equity Shares	Average cost of acquisition per Equity Share (in ₹)
1	Dharmesh Dashrathbhai Patel	10,72,500	0.91
2	Siddhant Jayantibhai Pawasia	15,40,000	0.91
3	Piyush Gordhanbhai Antala	12,65,000	0.91
4	Jaimik Mansukhlal Patel	8,80,000	0.85

and the Issue Price at the upper end of the Price Band is ₹ 128/- Per Equity Share.

2. The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end of the Price Band is 12.44.
3. Weighted Average Return on Net worth for Fiscals 2025, 2024, and 2023 is 77.51%.
4. The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

Period	Weighted Average Cost of Acquisition	Upper Band of the Price Band is (₹ 128/-) is "X" times the Weighted Average cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price (In ₹)
Last 1 year	Nil	Nil	Nil
Last 18 months	7.82	16.37	0-1076
Last 3 years	7.81	16.39	0-1076

5. **The Weighted average cost of acquisition (WACA) compared to floor price and cap price**

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor price (i.e. ₹ 120)	Cap price (i.e. ₹ 128)
Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan/employee stock option scheme and issuance of bonus shares, during the 18 months preceding the date of filing of the Prospectus, where such issuance is equal to or more than five per cent of the fully diluted paid-up share capital of our Company (calculated based on the preissue capital before such transaction/s and excluding employee stock options), in a single transaction or multiple transactions combined together over a span of rolling 30 days	7.82	15.35	16.37
Weighted average cost of acquisition for last 18 months for secondary sale / acquisition of shares equity / convertible securities), where promoter / promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) in our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.	N.A.	N.A.	N.A.
Since there were no secondary transactions of equity shares of our Company during the 18 months preceding the date of filing of the Prospectus, which are equal to or more than 5% of the fully diluted paid-up share capital of our Company, the information has been disclosed for price per share of our Company based on the last five secondary transactions where promoter /promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) on our Board, are a party to the transaction, not older than three years prior to the date of filing of the Prospectus irrespective of the size of the transaction.	N.A.	N.A.	N.A.

PROPOSED LISTING: NOVEMBER 14, 2025*

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. In terms of Regulation 256 of SEBI ICDR Regulations read with SEBI Circular No. CIR/CFD/POLICYCELL/11/2015, dated November 10, 2015 and Unified Payments Interface (UPI) introduced vide SEBI Circular Ref: SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, all Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" beginning on page 325 of Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on or before November 14, 2025*

*Subject to the receipt of listing and trading approval from the ("NSE EMERGE").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on November 06, 2025. The Company received 06 Anchor Investor Application Forms from 06 Anchor Investors for 9,45,000 Equity Shares. Such 06 Anchor Investors through 06 Anchor Investor Application Forms were allocated 6,09,000 Equity Shares at a price of ₹128 per Equity Share under the Anchor Investor Portion, aggregating to ₹ 7,79,52,000/-.

The Issue (excluding Anchor Investors Portion) received 21,539 Applications for 10,69,31,000 Equity Shares (before rejections) resulting in 69.3907 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

SR NO	CATEGORY	NO OF APPL	NO OF SHARES	RESERVED	NO OF TIMES SUBSCRIPTION	AMOUNT
1	MARKET MAKER	1	1,08,000	1,08,000	1.0000	1,38,24,000.00
2	QIB	43	3,93,32,000	4,08,000	96.4020	5,03,44,96,000.00
3	HNI UPTO 10 LAC	1,985	62,04,000	1,02,000	60.8235	79,39,76,000.00
4	HNI ABOVE 10 LAC	3,613	2,94,93,000	2,07,000	142.4783	3,77,51,04,000.00
5	INDIVIDUAL INVESTOR	15,897	3,17,94,000	7,16,000	44.4050	4,06,87,58,000.00
	TOTAL	21,539	10,69,31,000	15,41,000	69.3907	13,68,61,58,000.00

Final Demand:

A summary of the final demand as per NSE as on the Bid/ Offer Closing Date at different Bid prices is as under:

SR NO	RATE	SHARES	% to TOTAL	CUMULATIVE TOTAL	CUMULATIVE % TO TOTAL
1	120	2,01,000	0.17	2,01,000	0.17
2	121	16,000	0.01	2,17,000	0.19
3	122	10,000	0.01	2,27,000	0.19
4	123	4,000	0.00	2,31,000	0.20
5	125	48,000	0.04	2,79,000	0.24
6	126	26,000	0.02	3,05,000	0.26
7	127	20,000	0.02	3,25,000	0.28
8	128	11,61,01,000	99.72	11,64,26,000	100.00
	TOTAL	11,64,26,000	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being National Stock Exchange of India Limited on November 12, 2025.

1) **Allotment to Individual Investors who applies for minimum who applies for minimum application size (After Rejections):**

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE, The category has been subscribed to the extent of 44.0223 times for 3,15,20,000 Equity Shares. Total number of shares allotted in this category is 7,16,000 Equity Shares to 358 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	2000	15,760	100.00	3,15,20,000	100.00	2000	1:44	7,16,000
	TOTAL	15,760	100.00	3,15,20,000	100.00			7,16,000

2) **Allotment to Non-Institutional Investors (More than 2 lots and up to ₹ 1,000,000) (After Rejections):**

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 60.2451 times (after rejection) for 61,45,000 Equity Shares. Total number of shares allotted in this category is 1,02,000 Equity Shares to 34 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	3,000	1865	94.72	55,95,000	91.05	3,000	32:1865	96,000
2	5,000	37	1.88	1,85,000	3.01	3,000	1:37	3,000
3	4,000	28	1.42	1,12,000	1.82	3,000	0:28	0
4	6,000	20	1.02	1,20,000	1.95	3,000	0:20	0
5	7,000	19	0.96	1,33,000	2.16	3,000	0:19	0
6	0	All applicants from Serial no 03 to 05 for 1 (one) lot of 3000 shares				3,000	1:67	3,000
	TOTAL	1969	100.00	6145000	100.00			102000

Continued to next page....

Continued from previous page...

3) Allotment to Non-Institutional Investors (More than ₹ 1,000,000) (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 142.0483 times for 2,94,04,000 Equity Shares. Total number of shares allotted in this category is 2,07,000 Equity Shares to 69 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	8,000	3527	97.86	2,82,16,000	95.96	3,000	68:3527	2,04,000
2	9,000	25	0.69	2,25,000	0.77	3,000	0:25	0
3	10,000	19	0.53	1,90,000	0.65	3,000	0:19	0
4	11,000	4	0.11	44,000	0.15	3,000	0:4	0
5	12,000	7	0.19	84,000	0.29	3,000	0:7	0
6	13,000	1	0.03	13,000	0.04	3,000	0:1	0
7	15,000	2	0.06	30,000	0.10	3,000	0:2	0
8	16,000	4	0.11	64,000	0.22	3,000	0:4	0
9	20,000	1	0.03	20,000	0.07	3,000	0:1	0
10	21,000	4	0.11	84,000	0.29	3,000	0:4	0
11	23,000	1	0.03	23,000	0.08	3,000	0:1	0
12	29,000	1	0.03	29,000	0.10	3,000	0:1	0
13	30,000	1	0.03	30,000	0.10	3,000	0:1	0
14	32,000	2	0.06	64,000	0.22	3,000	0:2	0
15	41,000	1	0.03	41,000	0.14	3,000	0:1	0
16	42,000	1	0.03	42,000	0.14	3,000	0:1	0
17	66,000	1	0.03	66,000	0.22	3,000	0:1	0
18	67,000	1	0.03	67,000	0.23	3,000	0:1	0
19	72,000	1	0.03	72,000	0.24	3,000	0:1	0
20	0	All applicants from Serial no 02 to 19 for 1 (one) lot of 3000 shares				3,000	1:77	3,000
	TOTAL	**3604**	**100.00**	**29404000**	**100.00**			**207000**

4) Allotment to QIBs excluding Anchor Investors (After Rejections):

Allotment to QIBs, who have bid at the Issue Price of ₹ 128/- per Equity Share or above, has been done on a proportionate basis in consultation with NSE. The category was subscribed by 96.40 times i.e. for 3,93,32,000 Equity Shares. Total number of shares allotted in this category is 4,08,000 Equity Shares to 42 successful applicants. The category wise details of the Basis of Allotment are as under:

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC	VC'S	TOTAL
ALLOTMENT	-	-	9,000	29,000	2,09,000	1,52,000	9,000	4,08,000

5) Allocation to Market Maker:

The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 128/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed 1.00 times i.e. for 1,08,000 Equity Shares the total number of shares allotted in this category is 1,08,000 Equity Share. The category wise details of the Basis of Allotment are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	1,08,000	1	100.00	1,08,000	100.00	1,08,000	1:1	1,08,000
	TOTAL	**1**	**100.00**	1,08,000	**100.00**	1,08,000		1,08,000

6) Allotment to Anchor Investors (After Technical Rejection)

The Company in consultation with the BRLM has allocated 6,09,000 Equity Shares to 6 Anchor Investors at the Anchor Investor Issue Price of ₹ 128/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC	OTHERS	TOTAL
ALLOTMENT	-	-	-	79,000	4,45,000	85,000	-	6,09,000

The Board of Directors of our Company at its meeting held on November 12, 2025 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being National Stock Exchange of India Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBS have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before November 13, 2025 and In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before November 13, 2025 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from National Stock Exchange of India Limited and the trading of the Equity Shares is expected to commence on November 14, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated November 11, 2025 ("Prospectus").

NOTICE TO INVESTORS: CORRIGENDUM TO THE PROSPECTUS ("THE CORRIGENDUM")

With reference to the Prospectus dated November 11, 2025, filed with the RoC and submitted to the Stock Exchange and SEBI, attention to the investors is drawn to the following:

In furtherance to the disclosure made in the Number of Locked in shares (XII) appearing under the heading "Table I - Summary Statement holding of specified securities" in the chapter titled "Capital Structure" on page no. 78 of the Prospectus shall stand replaced as below:

Category (I)	Category of shareholder(II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV)+(V)+(VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a % of (A+B+C2)	Number of Voting Fresh held in each class of securities (IX)				No of shares underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full convertible securities (as a percentage of diluted share capital) (XI)= (VII)+(X) As a % of (A+B+C2)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)
								No of Voting (XIV) Rights			Total as a % of (A+B+C)			No (a)	As a % of total Shares held (b)	No (a)	As a % of total Shares held (b)	
								Class Equity	Class	Total								
A	Promoters & Promoters Group	7	55,00,000	0	0	55,00,000	92.68	55,00,000	0	55,00,000	92.68	0	0	55,00,000	92.68	0	0	55,00,000
B	Public	29	4,34,434	0	0	4,34,434	7.32	4,34,434	0	4,34,434	7.32	0	0	4,34,434	7.32	0	0	4,34,434
C	Non Promoters Non-Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C1	Shares underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C2	Shares held by Employee Trusts	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total (A+B+C)	**36**	**59,34,434**	-	-	**59,34,434**	**100.00**	**59,34,434**	-	**59,34,434**	**100.00**	-	**100.00**	**59,34,434**	**100.00**	-	-	**59,34,434**

The Prospectus shall be read in conjunction with this Corrigendum. The information in this Corrigendum supersedes the information provided in the Prospectus to the extent inconsistent with the information in the Prospectus. The Prospectus stands amended to the extent stated hereinabove. All capitalised terms used in this Corrigendum shall unless the context otherwise requires, have the same meanings as ascribed in the Prospectus.

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, MUFG INTIME INDIA PRIVATE LIMITED (Formerly Link Intime India Private Limited) at www.in.mpms.mufg.com

All future correspondence in this regards may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodge and payment details at the address of the Registrar given below:

MUFG

MUFG INTIME INDIA PRIVATE LIMITED
(Formerly Link Intime India Private Limited)
Address: C- 101, Embassy 247, L B S Marg, Vikhroli West, Mumbai -400083, Maharashtra;
Tel No.: +91 810 811 4949
Email Id: curislifesciences.smeipo@in.mpms.mufg.com
Investor Grievance Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: www.in.mpms.mufg.com **Contact Person:** Ms. Shanti Gopalkrishnan;
SEBI Registration No.: INR000004058; **CIN:** U67190MH1999PTC118368.

On behalf of Board of Directors
FOR, CURIS LIFESCIENCES LIMITED
Sd/-
Nikhil Purohit
Company Secretary & Compliance Officer

Place: Sanand, Gujarat
Date: November 13, 2025

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF CURIS LIFESCIENCES LIMITED

Disclaimer: Curis Lifesciences Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public Issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad on November 11, 2025 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme_offer and is available on the websites of the BRLM at www.finaaxcapital.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the chapter titled "Risk Factors" beginning on page 25 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

भारतीय खाद्य निगम **Food Corporation of India**

16–20, बाराखंभा लेन, नई दिल्ली–110001
16-20, Barakhamba Lane, New Delhi-110001

30 सितम्बर, 2025 को समाप्त तिमाही हेतु गैर–लेखापरीक्षित वित्तीय परिणामों का विवरण

Statement of Unaudited Financial Results for the Quarter Ended 30th September, 2025

विस्तृत वित्तीय परिणाम के लिए कृपया क्यूआर कोड स्कैन करें या एफसीआई / एनएसई वेबसाइट पर जाएं।

For detailed financial result please scan the QR Code or visit FCI Website (https://fci.gov.in/view/Accounts) /NSE Website.

KOTHARI SUGARS AND CHEMICALS LIMITED

Kothari SUGARS AND CHEMICALS LTD

Regd.Office:"Kothari Buildings", 115, Mahatma Gandhi Salai, Nungambakkam, Chennai - 600 034
CIN : L15421TN1960PLC004310 Phone No. 044-35225526 / 35225529
Email: secdept@hckgroup.com Website: www.hckotharigroup.com/kscl

Statement of Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2025

The Board of Directors of the Company, at their meeting held on November 13, 2025, approved the Unaudited financial results of the Company for the quarter and half year ended 30th September 2025 ("Financial Results").

The Financial results along with the Limited Review Report, have been posted on the Company's website **https://hckotharigroup.com/kscl/?q=node/22** (Path:www.hckotharigroup.com/kscl/investors/quarterlyresults) and can be accessed by scanning the QR code and the same is also available on the National Stock Exchange of India Ltd website at **www.nseindia.com**

for **Kothari Sugars and Chemicals Limited**

Arjun B. Kothari
Managing Director
DIN:07117816

Place : Chennai
Date : 13.11.2025

Note :
The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

RELIGARE ENTERPRISES LIMITED

CIN: L74899DL1984PLC146935
Regd. Office : First Floor, Office No. 101, 2E/23, Jhandewalan Extn., New Delhi, 110055

RELIGARE Values that bind

Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2025

(Rs. in Lakhs, unless otherwise stated)

	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025	September 30, 2025	June 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024	March 31, 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Revenue from Operations	88.67	24.01	342.85	112.68	629.41	625.67	2,06,421.17	1,86,138.13	1,95,185.65	3,92,559.30	3,66,140.45	7,35,423.64
2	Net Profit / (Loss) for the quarter/ period (before Tax, Exceptional and /or Extraordinary Items, and share in loss of joint venture)	(397.38)	(614.83)	(537.14)	(1,012.19)	(2,260.92)	(4,111.74)	5,745.07	573.25	6,743.54	6,318.32	10,009.28	24,330.01
3	Net Profit / (Loss) for the quarter/ year period Tax (after Exceptional and /or Extraordinary Items and share in loss of joint enture)	(397.38)	(614.83)	941.42	(1,012.19)	(642.89)	(3,754.28)	5,745.07	573.25	6,743.54	6,318.32	10,009.28	24,330.01
4	Total Comprehensive Income for the quarter/period (after Tax and non-Controlling Interest)	(391.20)	(621.67)	938.33	(1,012.85)	(658.19)	(3,809.02)	2,182.21	3,825.50	7,719.36	6,007.71	10,587.45	16,648.94
5	Equity Share Capital (Paid-up)	33,075.47	33,065.37	33,029.52	33,075.47	33,029.52	33,065.37	33,075.47	33,065.37	33,029.52	33,075.47	33,029.52	33,065.37
6	Other Equity (Excluding Revaluation Reserve) as shown in the Audited Balance Sheet	NA	NA	NA	NA	NA	1,75,912.59	NA	NA	NA	NA	NA	2,18,452.18
7	Earnings Per Share (EPS) before and after extraordinary items (of Rs 10/- each, fully paid up)												
	a. Basic EPS (Rs)	(0.12)	(0.19)	0.29	(0.31)	(0.19)	(1.14)	1.17	0.31	1.55	1.48	2.10	3.79
	b. Diluted EPS (Rs)	(0.12)	(0.19)	0.29	(0.31)	(0.19)	(1.14)	1.15	0.31	1.54	1.47	2.08	3.78

The above is an extract of the detailed format of Quarter and Half Year ended Financial Results filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarter and Half Year ended Financial Results is available on the Company's website **www.religare.com** and Stock Exchanges' website **www.nseindia.com** and **www.bseindia.com**.

For and on behalf of the Board of Directors
sd/-
Gurumurthy Ramanathan
Non-Executive & Non Independent Director

Place: New Delhi
Date : November 13, 2025

Phone: +91-11-11-41679692 | Website: www.religare.com | E-mail: investorservices@religare.com

---

यूको बैंक UCO BANK
Honours Your Trust
(A Govt. of India Undertaking)

Head Office – II
DIT - Procurement & Infrastructure
3 & 4, DD Block, Sector – 1, Salt Lake, Kolkata-700064

NOTICE INVITING TENDER

UCO Bank invites tender for the following item:
1. Selection of vendor for supply and installation of 10000 numbers of extended security update (ESU) licenses for existing PCs with windows 10 operating system

For any detail, please refer to **https://www.uco.bank.in** & **https://gem.gov.in**

(Deputy General Manager)
DIT- Procurement & Infrastructure

Date:- 14.11.2025

SUNITA BONDS AND HOLDINGS LIMITED

Regd off: 40B, Princep Street, Kolkata, West Bengal, India, 700072
Corp Off: 324A, Third Floor, Agarwal Plaa, Sec-14, Rohini, Delhi-110085
website: www.sunitabonds.com, **Email id:** abhlplc@gmail.com, **Tel.:** +91-9319125118
CIN: L65925WB1983PLC035697

Extracts of the Standalone Unaudited Financial Results For the Quarter and Half year ended September 30, 2025

(₹ in Lakh, except EPS)

S. No.	Particulars	Quarter Ended	Half year Ended	Corresponding 3 months ended in the previous year
		30/09/2025 (Unaudited)	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)
1.	Total income from operations	26.60	38.26	0.92
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	13.45	22.75	0.11
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	13.45	22.75	0.11
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	9.95	16.92	0.11
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	9.95	16.92	0.11
6.	Equity Share Capital	269.50	269.50	69.50
7.	Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of previous year)			
8.	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations) -			
	1. Basic:	0.37	0.63	0.02
	2. Diluted :	0.37	0.63	0.02

Note:
1. The above is an extract of the detailed format of unaudited Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Quarterly Financial Results are available on the Website of the Company i.e. (www.sunitabonds.com) and website of the stock Exchange(s) (www.cse-india.com) and (www.msei.in).
2. The above result have been reviewed by the audit committee and approved by the Board at their meeting held on13th November, 2025.
3. The Financial result have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act ,2013 read with IND -AS rules (As amended).

For and on behalf of the Board of Directors of
Sunita Bonds and Holdings Limited
Sd/-
Rohit Mittal
(Managing Director)
DIN: 02527072

Date: 13.11.2025
Place: Delhi

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTES AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Curis

Scan this QR code to view Prospectus

CURIS LIFESCIENCES LIMITED

CIN: U24230GJ2016PLC086559

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceuticals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation dated March 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/Deputy Registrar of Companies/Registrar of Companies, Central Processing Centre.

Registered Office: PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat -382110, India.
Company Secretary and Compliance Officer: Mr. Nikhil Purohit
Website: https://curisls.com/ **E-Mail:** cs@curisls.com **Telephone No:** +91 99045 22543

PROMOTERS OF OUR COMPANY: MR. DHARMESH DASHARATHBHAI PATEL, MR. SIDDHANT JAYANTIBHAI PAWASIA, MR. PIYUSH GORDHANBHAI ANTALA AND MR. JAIMIK MANSUKHLAL PATEL

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE ("NSE EMERGE")."

Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments. We are in business of manufacturing of pharmaceutical products.
For further details, please see chapter titled "Business Overview" beginning on page 133 of the Prospectus.

BASIS OF ALLOTMENT CUM CORRIGENDUM

INITIAL PUBLIC ISSUE OF 21,50,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF CURIS LIFESCIENCES LIMITED ("CURIS" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 2752.00 LAKHS ("THE ISSUE"), OF WHICH 1,08,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE AGGREGATING TO ₹ 138.24 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 20,42,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE AGGREGATING TO ₹ 2613.76 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.59 % AND 25.26 %, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10 EACH AND ISSUE PRICE IS ₹ 128 EACH
THE ISSUE PRICE IS 12.80 TIMES OF THE FACE VALUE OF THE EQUITY SHARE.
ANCHOR INVESTOR ISSUE PRICE: ₹ 128 PER EQUITY SHARE. THE ISSUE PRICE IS 12.80 TIMES OF THE FACE VALUE.

BID/ ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: NOVEMBER 6, 2025, THURSDAY
BID/ISSUE OPENED ON: NOVEMBER 7, 2025, FRIDAY
BID/ISSUE CLOSED ON: NOVEMBER 11, 2025, TUESDAY

RISKS TO INVESTORS

Summary description of key risk factors based on materiality

1. Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
2. As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
3. Our business operations are subject to fluctuations in raw material prices.
4. Any non-compliance or delays in Instalments of Outstanding loan may expose us to penalties from the Bank.
5. The company relies on a limited number of customers for its sales, and the loss of any major customer could adversely impact our revenue and profitability.
6. The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.
7. We depend on a limited number of States for a significant portion of our revenue from operations. The loss of any of our major customer in these States due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
8. Our Company is dependent on few countries. Loss of any of these large countries may affect our business operations.
9. A disclosure remark on compliance of Companies (Auditor's Report) Order, 2020 towards non payment of statutory dues in financial year ended March 31, 2020, March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024 have been noted by our Statutory Auditors in their reports.
10. Our Company depends on some of our Products which contributes more than 90% of the total revenue of the company. The loss of any of this major Products due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.

For details refer to chapter titled "Risk Factors" beginning on page 25 of the Prospectus.

1. **The Average Cost of acquisition of Equity Shares held by our Promoters is as follows:**

Sr. No.	Name	No. of Equity Shares	Average cost of acquisition per Equity Share (in ₹)
1	Dharmesh Dashrathbhai Patel	10,72,500	0.91
2	Siddhant Jayantibhai Pawasia	15,40,000	0.91
3	Piyush Gordhanbhai Antala	12,65,000	0.91
4	Jaimik Mansukhlal Patel	8,80,000	0.85

and the Issue Price at the upper end of the Price Band is ₹ 128/- Per Equity Share.

2. The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end of the Price Band is 12.44.
3. Weighted Average Return on Net worth for Fiscals 2025, 2024, and 2023 is 77.51%.
4. The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

Period	Weighted Average Cost of Acquisition	Upper Band of the Price Band is (₹ 128/-) is "X" times the Weighted Average cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price (In ₹)
Last 1 year	Nil	Nil	Nil
Last 18 months	7.82	16.37	0-1076
Last 3 years	7.81	16.39	0-1076

5. **The Weighted average cost of acquisition (WACA) compared to floor price and cap price**

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor price (i.e. ₹ 120)	Cap price (i.e. ₹ 128)
Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan/employee stock option scheme and issuance of bonus shares, during the 18 months preceding the date of filing of the Prospectus, where such issuance is equal to or more than five per cent of the fully diluted paid-up share capital of our Company (calculated based on the preissue capital before such transaction/s and excluding employee stock options), in a single transaction or multiple transactions combined together over a span of rolling 30 days	7.82	15.35	16.37
Weighted average cost of acquisition for last 18 months for secondary sale / acquisition of shares equity / convertible securities), where promoter / promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) in our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.	N.A.	N.A.	N.A.
Since there were no secondary transactions of equity shares of our Company during the 18 months preceding the date of filing of the Prospectus, which are equal to or more than 5% of the fully diluted paid-up share capital of our Company, the information has been disclosed for price per share of our Company based on the last five secondary transactions where promoter /promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) on our Board, are a party to the transaction, not older than three years prior to the date of filing of the Prospectus irrespective of the size of the transaction.	N.A.	N.A.	N.A.

PROPOSED LISTING: NOVEMBER 14, 2025*

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. In terms of Regulation 256 of SEBI ICDR Regulations read with SEBI Circular No. CIR/CFD/POLICYCELL/11/2015, dated November 10, 2015 and Unified Payments Interface (UPI) introduced vide SEBI Circular Ref: SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, all Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" beginning on page 325 of Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on or before November 14, 2025*

*Subject to the receipt of listing and trading approval from the ("NSE EMERGE").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on November 06, 2025. The Company received 06 Anchor Investor Application Forms from 06 Anchor Investors for 9,45,000 Equity Shares. Such 06 Anchor Investors through 06 Anchor Investor Application Forms were allocated 6,09,000 Equity Shares at a price of ₹128 per Equity Share under the Anchor Investor Portion, aggregating to ₹ 7,79,52,000/-.

The Issue (excluding Anchor Investors Portion) received 21,539 Applications for 10,69,31,000 Equity Shares (before rejections) resulting in 69.3907 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

SR NO	CATEGORY	NO OF APPL	NO OF SHARES	RESERVED	NO OF TIMES SUBSCRIPTION	AMOUNT
1	MARKET MAKER	1	1,08,000	1,08,000	1.0000	1,38,24,000.00
2	QIB	43	3,93,32,000	4,08,000	96.4020	5,03,44,96,000.00
3	HNI UPTO 10 LAC	1,985	62,04,000	1,02,000	60.8235	79,39,76,000.00
4	HNI ABOVE 10 LAC	3,613	2,94,93,000	2,07,000	142.4783	3,77,51,04,000.00
5	INDIVIDUAL INVESTOR	15,897	3,17,94,000	7,16,000	44.4050	4,06,87,58,000.00
	TOTAL	**21,539**	**10,69,31,000**	**15,41,000**	**69.3907**	**13,68,61,58,000.00**

Final Demand:
A summary of the final demand as per NSE as on the Bid/ Offer Closing Date at different Bid prices is as under:

SR NO	RATE	SHARES	% to TOTAL	CUMULATIVE TOTAL	CUMULATIVE % TO TOTAL
1	120	2,01,000	0.17	2,01,000	0.17
2	121	16,000	0.01	2,17,000	0.19
3	122	10,000	0.01	2,27,000	0.19
4	123	4,000	0.00	2,31,000	0.20
5	125	48,000	0.04	2,79,000	0.24
6	126	26,000	0.02	3,05,000	0.26
7	127	20,000	0.02	3,25,000	0.28
8	128	11,61,01,000	99.72	11,64,26,000	100.00
	TOTAL	**11,64,26,000**	**100.00**		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being National Stock Exchange of India Limited on November 12, 2025.

1) **Allotment to Individual Investors who applies for minimum who applies for minimum application size (After Rejections):**

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 44.0223 times for 3,15,20,000 Equity Shares. Total number of shares allotted in this category is 7,16,000 Equity Shares to 358 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	2000	15,760	100.00	3,15,20,000	100.00	2000	1:44	7,16,000
	TOTAL	**15,760**	**100.00**	**3,15,20,000**	**100.00**			**7,16,000**

2) **Allotment to Non-Institutional Investors (More than 2 lots and up to ₹ 1,000,000) (After Rejections):**

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 60.2451 times (after rejection) for 61,45,000 Equity Shares: Total number of shares allotted in this category is 1,02,000 Equity Shares to 34 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	3,000	1865	94.72	55,95,000	91.05	3,000	32:1865	96,000
2	5,000	37	1.88	1,85,000	3.01	3,000	1:37	3,000
3	4,000	28	1.42	1,12,000	1.82	3,000	0:28	0
4	6,000	20	1.02	1,20,000	1.95	3,000	0:20	0
5	7,000	19	0.96	1,33,000	2.16	3,000	0:19	0
6	0	All applicants from Serial no 03 to 05 for 1 (one) lot of 3000 shares				3,000	1:67	3,000
	TOTAL	**1969**	**100.00**	**6145000**	**100.00**			**102000**

Continued to next page.....

Continued from previous page.....

3) Allotment to Non-Institutional Investors (More than ₹ 1,000,000) (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 142.0483 times for 2,94,04,000 Equity Shares. Total number of shares allotted in this category is 2,07,000 Equity Shares to 69 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	8,000	3527	97.86	2,82,16,000	95.96	3,000	68:3527	2,04,000
2	9,000	25	0.69	2,25,000	0.77	3,000	0:25	0
3	10,000	19	0.53	1,90,000	0.65	3,000	0:19	0
4	11,000	4	0.11	44,000	0.15	3,000	0:4	0
5	12,000	7	0.19	84,000	0.29	3,000	0:7	0
6	13,000	1	0.03	13,000	0.04	3,000	0:1	0
7	15,000	2	0.06	30,000	0.10	3,000	0:2	0
8	16,000	4	0.11	64,000	0.22	3,000	0:4	0
9	20,000	1	0.03	20,000	0.07	3,000	0:1	0
10	21,000	4	0.11	84,000	0.29	3,000	0:4	0
11	23,000	1	0.03	23,000	0.08	3,000	0:1	0
12	29,000	1	0.03	29,000	0.10	3,000	0:1	0
13	30,000	1	0.03	30,000	0.10	3,000	0:1	0
14	32,000	2	0.06	64,000	0.22	3,000	0:2	0
15	41,000	1	0.03	41,000	0.14	3,000	0:1	0
16	42,000	1	0.03	42,000	0.14	3,000	0:1	0
17	66,000	1	0.03	66,000	0.22	3,000	0:1	0
18	67,000	1	0.03	67,000	0.23	3,000	0:1	0
19	72,000	1	0.03	72,000	0.24	3,000	0:1	0
20	0	All applicants from Serial no 02 to 19 for 1 (one) lot of 3000 shares				3,000	1:77	3,000
	TOTAL	**3604**	**100.00**	**29404000**	**100.00**			**207000**

4) Allotment to QIBs excluding Anchor Investors (After Rejections):

Allotment to QIBs, who have bid at the Issue Price of ₹ 128/- per Equity Share or above, has been done on a proportionate basis in consultation with NSE. The category was subscribed by 96.40 times i.e. for 3,93,32,000 Equity Shares. Total number of shares allotted in this category is 4,08,000 Equity Shares to 42 successful applicants. The category wise details of the Basis of Allotment are as under:

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC	VC'S	TOTAL
ALLOTMENT	-	-	9,000	29,000	2,09,000	1,52,000	9,000	4,08,000

5) Allocation to Market Maker:

The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 128/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed 1.00 times i.e. for 1,08,000 Equity Shares the total number of shares allotted in this category is 1,08,000 Equity Share. The category wise details of the Basis of Allotment are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	1,08,000	1	100.00	1,08,000	100.00	1,08,000	1:1	1,08,000
	TOTAL	**1**	**100.00**	1,08,000	**100.00**	1,08,000		1,08,000

6) Allotment to Anchor Investors (After Technical Rejection)

The Company in consultation with the BRLM has allocated 6,09,000 Equity Shares to 6 Anchor Investors at the Anchor Investor Issue Price of ₹ 128/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC	OTHERS	TOTAL
ALLOTMENT	-	-	-	79,000	4,45,000	85,000	-	6,09,000

The Board of Directors of our Company at its meeting held on November 12, 2025 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being National Stock Exchange of India Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBS have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before November 13, 2025 and in case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before November 13, 2025 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from National Stock Exchange of India Limited and the trading of the Equity Shares is expected to commence on November 14, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated November 11, 2025 ("Prospectus").

NOTICE TO INVESTORS: CORRIGENDUM TO THE PROSPECTUS ("THE CORRIGENDUM")

With reference to the Prospectus dated November 11, 2025, filed with the RoC and submitted to the Stock Exchange and SEBI, attention to the investors is drawn to the following:

In furtherance to the disclosure made in the Number of Locked in shares (XII) appearing under the heading "Table I - Summary Statement holding of specified securities" in the chapter titled "Capital Structure" on page no. 78 of the Prospectus shall stand replaced as below:

Category (I)	Category of shareholder(II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV)+(V)+(VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a % of (A+B+C2)	Number of Voting Fresh held in each class of securities (IX)				No of shares underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full convertible securities (as a percentage of diluted share capital) (XI)= (VII)+(X) As a % of (A+B+C2)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)
								No of Voting (XIV) Rights			Total as a % of (A+B+C)			No (a)	As a % of total Shares held (b)	No (a)	As a % of total Shares held (b)	
								Class Equity	Class	Total								
A	Promoters & Promoters Group	7	55,00,000	0	0	55,00,000	92.68	55,00,000	0	55,00,000	92.68	0	0	55,00,000	92.68	0	0	55,00,000
B	Public	29	4,34,434	0	0	4,34,434	7.32	4,34,434	0	4,34,434	7.32	0	0	4,34,434	7.32	0	0	4,34,434
C	Non Promoters Non-Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C1	Shares underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C2	Shares held by Employee Trusts	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total (A+B+C)	**36**	**59,34,434**	-	-	**59,34,434**	**100.00**	**59,34,434**	-	**59,34,434**	**100.00**	-	**100.00**	**59,34,434**	**100.00**	-	-	**59,34,434**

The Prospectus shall be read in conjunction with this Corrigendum. The information in this Corrigendum supersedes the information provided in the Prospectus to the extent inconsistent with the information in the Prospectus. The Prospectus stands amended to the extent stated hereinabove. All capitalised terms used in this Corrigendum shall unless the context otherwise requires, have the same meanings as ascribed in the Prospectus.

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, MUFG INTIME INDIA PRIVATE LIMITED (Formerly Link Intime India Private Limited) at www.in.mpms.mufg.com

All future correspondence in this regards may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodge and payment details at the address of the Registrar given below:

MUFG

MUFG INTIME INDIA PRIVATE LIMITED
(Formerly Link Intime India Private Limited)
Address: C- 101, Embassy 247, L B S Marg, Vikhroli West, Mumbai -400083, Maharashtra;
Tel No.: +91 810 811 4949
Email Id: curislifesciences.smeipo@in.mpms.mufg.com
Investor Grievance Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: www.in.mpms.mufg.com **Contact Person:** Ms. Shanti Gopalkrishnan;
SEBI Registration No.: INR000004058; **CIN:** U67190MH1999PTC118368.

On behalf of Board of Directors
FOR, CURIS LIFESCIENCES LIMITED
Sd/-
Nikhil Purohit
Company Secretary & Compliance Officer

Place: Sanand, Gujarat
Date: November 13, 2025

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF CURIS LIFESCIENCES LIMITED

Disclaimer: Curis Lifesciences Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad on November 11, 2025 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme_offer and is available on the websites of the BRLM at www.finaxcapital.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the chapter titled "Risk Factors" beginning on page 25 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

THE BIGGEST CAPITAL ONE CAN POSSESS KNOWLEDGE

FINANCIAL EXPRESS
Read to Lead

THE INDOGULF GROUP

INDOGULF CROPSCIENCES LIMITED

CIN: L74899DL1993PLC051854
Regd. Office : 501, Gopal Heights, Netaji Subhash Place, Delhi - 110034 (INDIA)
Website: www.groupindogulf.com; **Email:** info@groupindogulf.com

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEP 2025

(₹ in Millions, unless otherwise stated)

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter ended 30th Sep, 2025 (Unaudited)	Quarter ended 30th June, 2025 (Unaudited)	Quarter ended 30th Sep, 2024 (Unaudited)	Half Year ended 30th Sep, 2025 (Unaudited)	Half Year ended 30th Sep, 2024 (Unaudited)	Year ended 31st March, 2025 (Audited)	Quarter ended 30th Sep, 2025 (Unaudited)	Quarter ended 30th June, 2025 (Unaudited)	Quarter ended 30th Sep, 2024 (Unaudited)	Half Year ended 30th Sep, 2025 (Unaudited)	Half Year ended 30th Sep, 2024 (Unaudited)	Quarter ended 31st March, 2025 (Unaudited)
1	Total Income	2,484.39	1,861.69	2,399.96	4,346.08	3,725.80	5,966.76	2,502.98	1,903.05	2,338.91	4,406.03	3,664.38	5,944.75
2	Net profit before tax	254.58	36.11	232.28	290.69	254.43	453.41	271.16	46.49	227.38	317.65	247.79	445.70
3	Net profit after tax	194.55	29.54	173.20	224.09	186.94	320.85	206.85	38.67	166.71	245.52	180.18	314.72
4	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	194.94	29.93	173.56	224.87	187.79	322.40	207.24	39.06	167.19	246.30	181.15	316.27
5	Paid-up equity share capital (Face Value ₹ 10/- each)	632.24	487.87	487.87	632.24	487.87	487.87	632.24	487.87	487.87	632.24	487.87	487.87
6	Other equity excluding revaluation reserves	1,453.63	2,304.99	2,140.47	3,758.62	2,140.47	2,275.06	3,769.88	2,303.96	168.69	3,769.88	2,131.27	2,264.90
7	Earnings Per Share(of ₹ 10/- each) in ₹ (not annualised)							1.73	0.80	4.07	2.05	4.40	7.02
	Basic	1.62	0.61	4.23	1.87	4.56	7.16	1.73	0.80	4.07	2.05	4.40	7.02
	Diluted	1.62	0.61	4.23	1.87	4.56	7.16						

Notes:

1. The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the Stock Exchange websites. (www.bseindia.com and www.nseindia.com) and on company's website (www.groupindogulf.com).
2. The above financial results have been reviewed and recommended by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on 12 Nov 2025
3. The Limited Review required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been completed by the auditors of the Company.

For and on Behalf of Board of Directors of
Indogulf Cropsciences Limited

Sanjay Aggarwal
(Managing Director)

Place: DELHI
Date: 12th November, 2025

CONCEPT

पंजाब नैशनल बैंक .....भरोसे का प्रतीक (A GOVERNMENT OF INDIA UNDERTAKING) punjab national bank ...the name you can BANK upon!

आस्ति वसूली प्रबंधन शाखा, गाजियाबाद,
केजे–13, कविनगर, गाजियाबाद – 201001,
मो. : 9560155582, ई–मेल: cs8228@pnb.co.in

अचल सम्पत्तियों की ई–नीलामी हेतु बिक्री सूचना

प्रतिभूति हित (प्रवर्तन) नियम 2002 के नियम 8(6) के परन्तुक के साथ पठित वित्तीय आस्तियों का प्रतिभूतिकरण और पुनर्गठन तथा प्रतिभूति हित का प्रवर्तन अधिनियम, 2002 के अधीन अचल सम्पत्तियों के विक्रय हेतु ई–नीलामी विक्रय नोटिस.

आम जनता को और विशेष रूप से कर्जदार और गारंटर्स को यह नोटिस दिया जाता है कि नीचे वर्णित अचल सम्पत्तियां जो प्रतिभूत लेनदार के पास बंधक / प्रभारित है, का सांकेतिक / वास्तविक कब्जा(नीचे वर्णित अनुसार), प्रतिभूत लेनदार पंजाब नेशनल बैंक के प्राधिकृत अधिकारी द्वारा लिया गया है, को "जहां है, जैसा है और जो कुछ भी है" के आधार पर बेचा जाएगा। बकाया राशि की वसूली, कर्जदार(रों) और गारंटर(रों), आरक्षित मूल्य और धरोहर राशि का विवरण नीचे दी गई तालिका के अनुसार

प्रत्याभूत परिसम्पत्तियों की बिक्री की अनुसूची

क्र. सं.	शाखा का नाम / खाते का नाम / कर्जदार / गारंटर्स खाते का नाम एवं पता	(E) सरफासी अधिनियम 2002 की धारा 13(2) के अंतर्गत मांग सूचना की तिथि / (F) सरफासी अधिनियम 2002 की धारा 13(4) के अंतर्गत कब्जा की तिथि / (G) मांग सूचना के अनुसार बकाया राशि / (H) कब्जा की स्थिति सांकेतिक / भौतिक / दमनात्मक	अचल सम्पत्तियों का विवरण – बंधक / स्वामी के नाम (सम्पत्तियों के बंधककर्ता)	(A) आरक्षित मूल्य / (B) ईएमडी / (C) बोली वृद्धि राशि	नीलामी की तिथि एवं समय	प्रतिभूति लेनदार के संज्ञान में ऋण भारों का विवरण
1.	**लोहा मंडी(613300)** **श्रीमती आरुषि जैन पुत्री श्री रवि कुमार जैन (उधारकर्ता)** खाता संख्या–613300NC00002248; **निवास** – फ्लैट संख्या 302, तृतीय तल "राज अपार्टमेंट" ग्राम मेहमा सराय उर्फ कोट, गाजियाबाद, उत्तर प्रदेश–201102 **इसके अलावा** – मकान संख्या –132, तुराब नगर, गाजियाबाद, उत्तर प्रदेश–201001 **श्रीमती अर्चना जैन, पत्नी श्री रवि कुमार जैन (सह–उधारकर्ता)** फ्लैट संख्या 302, तृतीय तल राज अपार्टमेंट, ग्राम मेहमा सराय उर्फ कोट, गाजियाबाद, उत्तर प्रदेश–201102 **इसके अलावा** मकान संख्या –132, तुराब नगर, गाजियाबाद, उत्तर प्रदेश–201001 **श्री तरुण गोयल, पुत्र श्री रामअवतार गोयल (गारंटर)** निवासी 21/17, लेबर कॉलोनी लाल क्वार्टर गाजियाबाद उ.प्र. 201001	(E) 30.12.2024 (F) 15.10.2024 (G) रु. 6501412.00 पलस भविष्य का ब्याज और उस पर खर्च (H) सांकेतिक	संपत्ति के सभी भाग और पार्सल जिसमें आवासीय फ्लैट नंबर 302, तीसरी मंजिल (छत के अधिकार के साथ), खसरा नंबर 27/1, राज अपार्टमेंट ग्राम मेहमा सराय उर्फ कोट, तहसील और जिला– गाजियाबाद, उत्तर प्रदेश –201102 में स्थित है। क्षेत्रफल 67.22 वर्ग मीटर या 81 वर्ग गज आरुषि जैन पुत्री रवि कुमार जैन के नाम पर। निम्नानुसार परिबद्ध:– **पूर्व:** दीवार मुस्तका बंधु, दूसरे मालिक की संपत्ति। **पश्चिम:** दीवार मुस्तका बंधु, दूसरे मालिक की संपत्ति। **उत्तर:** भूतल पर, 20 फुट चौड़ी सड़क, **दक्षिण:** दीवार मुस्तका बंधु, विक्रेता की संपत्ति। **(सांकेतिक कब्जा)**	(A) रु. 24.45 लाख (B) रु. 2.45 लाख (C) रु. 50,000/-	**17.12.2025** पूर्वाह्न 11.00 बजे से अपराह्न 04.00 बजे	ज्ञात नहीं

ई–नीलामी बिक्री के संक्षिप्त नियम एवं शर्तें : (1) बिक्री, प्रतिभूति हित (प्रवर्तन) नियमावली 2002 में वर्णित नियमों एवं शर्तों के अधीन होगी। (2) **सम्पत्तियां को "जो है जहाँ है", "जैसी है जो कुछ भी है" एवं "दायित्व रहित आधार पर" बेचा जा रहा है।** (3) ऊपर वर्णित अनुसूची में विनिर्दिष्ट सुरक्षित परिसंपत्तियों का विवरण, प्राधिकृत अधिकारी की सर्वश्रेष्ठ जानकारी के अनुसार दर्शाई गई है, किंतु प्राधिकृत अधिकारी इस उद्घोषणा में किसी त्रुटि, गलत बयान या चूक के लिए जवाबदेह नहीं होगा। (4) नीलामी ई–नीलामी प्लेटफार्म वेबसाईट **https://baanknet.com** के माध्यम से ऊपर वर्णित दिनांकों को आयोजित की जाएगी। (5) अधिक विवरण तथा सम्पूर्ण नियमों व शर्तों के लिए कृपया निम्नलिखित वेबसाइट्स : **https://baanknet.com & www.pnbindia.in** देखें। (6) सभी सांविधिक बकाया / अटैचमेंट शुल्क / पंजीकरण शुल्क, स्टांप शुल्क, कर इत्यादि अन्य बकाया, खरीददारों को वहन करना होगा। प्राधिकृत अधिकारी या बैंक किसी भी शुल्क के लिए जिम्मेदार नहीं होगा। ऋणभार में ग्रहणाधिकार सांविधिक बकाया या किसी अन्य के लिए संपत्ति (ई–नीलामी) के संबंध में जो बैंक को ज्ञात नहीं है, इच्छुक बोलीदाता को सलाह दी जाती है कि वे वैधानिक देनदारियों, संपत्ति कर की बकाया राशि, बिजली बकाया इत्यादि संपत्ति पर भार के संबंध में स्वतंत्र पूछताछ करें।

सरफेसी अधिनियम, 2002 के नियम 8(6) के तहत वैधानिक बिक्री सूचना

दिनांक: **13.11.2025**, स्थान : गाजियाबाद

श्री सुशील कुमार कर्ण, मो. 9560155582 (प्राधिकृत अधिकारी), पंजाब नैशनल बैंक

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTES AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Curis

Scan this QR code to view Prospectus

CURIS LIFESCIENCES LIMITED

CIN: U24230GJ2016PLC086559

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceuticals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation dated March 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/Deputy Registrar of Companies/Registrar of Companies, Central Processing Centre.

Registered Office: PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat -382110, India.
Company Secretary and Compliance Officer: Mr. Nikhil Purohit
Website: https://curisls.com/ **E-Mail:** cs@curisls.com **Telephone No:** +91 99045 22543

PROMOTERS OF OUR COMPANY: MR. DHARMESH DASHARATHBHAI PATEL, MR. SIDDHANT JAYANTIBHAI PAWASIA, MR. PIYUSH GORDHANBHAI ANTALA AND MR. JAIMIK MANSUKHLAL PATEL

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE ("NSE EMERGE")."

Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments. We are in business of manufacturing of pharmaceutical products.
For further details, please see chapter titled "Business Overview" beginning on page 133 of the Prospectus.

BASIS OF ALLOTMENT CUM CORRIGENDUM

INITIAL PUBLIC ISSUE OF 21,50,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF CURIS LIFESCIENCES LIMITED ("CURIS" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 2752.00 LAKHS ("THE ISSUE"), OF WHICH 1,08,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE AGGREGATING TO ₹ 138.24 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 20,42,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE AGGREGATING TO ₹ 2613.76 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.59 % AND 25.26 %, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10 EACH AND ISSUE PRICE IS ₹ 128 EACH
THE ISSUE PRICE IS 12.80 TIMES OF THE FACE VALUE OF THE EQUITY SHARE.
ANCHOR INVESTOR ISSUE PRICE: ₹ 128 PER EQUITY SHARE. THE ISSUE PRICE IS 12.80 TIMES OF THE FACE VALUE.

BID/ ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE WAS: NOVEMBER 6, 2025, THURSDAY
BID/ISSUE OPENED ON: NOVEMBER 7, 2025, FRIDAY
BID/ISSUE CLOSED ON: NOVEMBER 11, 2025, TUESDAY

RISKS TO INVESTORS

Summary description of key risk factors based on materiality

1. Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
2. As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
3. Our business operations are subject to fluctuations in raw material prices.
4. Any non-compliance or delays in Instalments of Outstanding loan may expose us to penalties from the Bank.
5. The company relies on a limited number of customers for its sales. and the loss of any major customer could adversely impact our revenue and profitability.
6. The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.
7. We depend on a limited number of States for a significant portion of our revenue from operations. The loss of any of our major customer in these States due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
8. Our Company is dependent on few countries. Loss of any of these large countries may affect our business operations.
9. A disclosure remark on compliance of Companies (Auditor's Report) Order, 2020 towards non payment of statutory dues in financial year ended March 31, 2020, March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024 have been noted by our Statutory Auditors in their reports.
10. Our Company depends on some of our Products which contributes more than 90% of the total revenue of the company. The loss of any of this major Products due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.

For details refer to chapter titled "Risk Factors" beginning on page 25 of the Prospectus.

1. **The Average Cost of acquisition of Equity Shares held by our Promoters is as follows:**

Sr. No.	Name	No. of Equity Shares	Average cost of acquisition per Equity Share (in ₹)
1	Dharmesh Dashrathbhai Patel	10,72,500	0.91
2	Siddhant Jayantibhai Pawasia	15,40,000	0.91
3	Piyush Gordhanbhai Antala	12,65,000	0.91
4	Jaimik Mansukhlal Patel	8,80,000	0.85

and the Issue Price at the upper end of the Price Band is ₹ 128/- Per Equity Share.

2. The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end of the Price Band is 12.44.
3. Weighted Average Return on Net worth for Fiscals 2025, 2024, and 2023 is 77.51%.
4. The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

Period	Weighted Average Cost of Acquisition	Upper Band of the Price Band is (₹ 128/-) is "X" times the Weighted Average cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price (in ₹)
Last 1 year	Nil	Nil	Nil
Last 18 months	7.82	16.37	0-1076
Last 3 years	7.81	16.39	0-1076

5. **The Weighted average cost of acquisition (WACA) compared to floor price and cap price**

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor price (i.e. ₹ 120)	Cap price (i.e. ₹ 128)
Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan/employee stock option scheme and issuance of bonus shares, during the 18 months preceding the date of filing of the Prospectus, where such issuance is equal to or more than five per cent of the fully diluted paid-up share capital of our Company (calculated based on the preissue capital before such transaction/s and excluding employee stock options), in a single transaction or multiple transactions combined together over a span of rolling 30 days	7.82	15.35	16.37
Weighted average cost of acquisition for last 18 months for secondary sale / acquisition of shares equity / convertible securities), where promoter / promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) in our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.	N.A.	N.A.	N.A.
Since there were no secondary transactions of equity shares of our Company during the 18 months preceding the date of filing of the Prospectus, which are equal to or more than 5% of the fully diluted paid-up share capital of our Company, the information has been disclosed for price per share of our Company based on the last five secondary transactions where promoter /promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) on our Board, are a party to the transaction, not older than three years prior to the date of filing of the Prospectus irrespective of the size of the transaction.	N.A.	N.A.	N.A.

PROPOSED LISTING: NOVEMBER 14, 2025*

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. In terms of Regulation 256 of SEBI ICDR Regulations read with SEBI Circular No. CIR/CFD/POLICYCELL/11/2015, dated November 10, 2015 and Unified Payments Interface (UPI) introduced vide SEBI Circular Ref: SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, all Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" beginning on page 325 of Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on or before November 14, 2025*

*Subject to the receipt of listing and trading approval from the ("NSE EMERGE").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on November 06, 2025. The Company received 06 Anchor Investor Application Forms from 06 Anchor Investors for 9,45,000 Equity Shares. Such 06 Anchor Investors through 06 Anchor Investor Application Forms were allocated 6,09,000 Equity Shares at a price of ₹128 per Equity Share under the Anchor Investor Portion, aggregating to ₹ 7,79,52,000/-.

The Issue (excluding Anchor Investors Portion) received 21,539 Applications for 10,69,31,000 Equity Shares (before rejections) resulting in 69.3907 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

SR NO	CATEGORY	NO OF APPL	NO OF SHARES	RESERVED	NO OF TIMES SUBSCRIPTION	AMOUNT
1	MARKET MAKER	1	1,08,000	1,08,000	1.0000	1,38,24,000.00
2	QIB	43	3,93,32,000	4,08,000	96.4020	5,03,44,96,000.00
3	HNI UPTO 10 LAC	1,985	62,04,000	1,02,000	60.8235	79,39,76,000.00
4	HNI ABOVE 10 LAC	3,613	2,94,93,000	2,07,000	142.4783	3,77,51,04,000.00
5	INDIVIDUAL INVESTOR	15,897	3,17,94,000	7,16,000	44.4050	4,06,87,58,000.00
	TOTAL	21,539	10,69,31,000	15,41,000	69.3907	13,68,61,58,000.00

Final Demand:
A summary of the final demand as per NSE as on the Bid/ Offer Closing Date at different Bid prices is as under:

SR NO	RATE	SHARES	% to TOTAL	CUMULATIVE TOTAL	CUMULATIVE % TO TOTAL
1	120	2,01,000	0.17	2,01,000	0.17
2	121	16,000	0.01	2,17,000	0.19
3	122	10,000	0.01	2,27,000	0.19
4	123	4,000	0.00	2,31,000	0.20
5	125	48,000	0.04	2,79,000	0.24
6	126	26,000	0.02	3,05,000	0.26
7	127	20,000	0.02	3,25,000	0.28
8	128	11,61,01,000	99.72	11,64,26,000	100.00
	TOTAL	11,64,26,000	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being National Stock Exchange of India Limited on November 12, 2025.

1) **Allotment to Individual Investors who applies for minimum who applies for minimum application size (After Rejections):**

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE, The category has been subscribed to the extent of 44.0223 times for 3,15,20,000 Equity Shares. Total number of shares allotted in this category is 7,16,000 Equity Shares to 358 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	2000	15,760	100.00	3,15,20,000	100.00	2000	1:44	7,16,000
	TOTAL	15,760	100.00	3,15,20,000	100.00			7,16,000

2) **Allotment to Non-Institutional Investors (More than 2 lots and up to ₹ 1,000,000) (After Rejections):**

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 60.2451 times (after rejection) for 61,45,000 Equity Shares. Total number of shares allotted in this category is 1,02,000 Equity Shares to 34 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	3,000	1865	94.72	55,95,000	91.05	3,000	32:1865	96,000
2	5,000	37	1.88	1,85,000	3.01	3,000	1:37	3,000
3	4,000	28	1.42	1,12,000	1.82	3,000	0:28	0
4	6,000	20	1.02	1,20,000	1.95	3,000	0:20	0
5	7,000	19	0.96	1,33,000	2.16	3,000	0:19	0
6	0	All applicants from Serial no 03 to 05 for 1 (one) lot of 3000 shares				3,000	1:67	3,000
	TOTAL	1969	100.00	6145000	100.00			102000

Continued to next page.....

Continued from previous page...

3) Allotment to Non-Institutional Investors (More than ₹ 1,000,000) (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 142.0483 times for 2,94,04,000 Equity Shares. Total number of shares allotted in this category is 2,07,000 Equity Shares to 69 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	8,000	3527	97.86	2,82,16,000	95.96	3,000	68.3527	2,04,000
2	9,000	25	0.69	2,25,000	0.77	3,000	0:25	0
3	10,000	19	0.53	1,90,000	0.65	3,000	0:19	0
4	11,000	4	0.11	44,000	0.15	3,000	0:4	0
5	12,000	7	0.19	84,000	0.29	3,000	0:7	0
6	13,000	1	0.03	13,000	0.04	3,000	0:1	0
7	15,000	2	0.06	30,000	0.10	3,000	0:2	0
8	16,000	4	0.11	64,000	0.22	3,000	0:4	0
9	20,000	1	0.03	20,000	0.07	3,000	0:1	0
10	21,000	4	0.11	84,000	0.29	3,000	0:4	0
11	23,000	1	0.03	23,000	0.08	3,000	0:1	0
12	29,000	1	0.03	29,000	0.10	3,000	0:1	0
13	30,000	1	0.03	30,000	0.10	3,000	0:1	0
14	32,000	2	0.06	64,000	0.22	3,000	0:2	0
15	41,000	1	0.03	41,000	0.14	3,000	0:1	0
16	42,000	1	0.03	42,000	0.14	3,000	0:1	0
17	66,000	1	0.03	66,000	0.22	3,000	0:1	0
18	67,000	1	0.03	67,000	0.23	3,000	0:1	0
19	72,000	1	0.03	72,000	0.24	3,000	0:1	0
20	0	All applicants from Serial no 02 to 19 for 1 (one) lot of 3000 shares				3,000	1:77	3,000
	TOTAL	**3604**	**100.00**	**29404000**	**100.00**			**207000**

4) Allotment to QIBs excluding Anchor Investors (After Rejections):

Allotment to QIBs, who have bid at the Issue Price of ₹ 128/- per Equity Share or above, has been done on a proportionate basis in consultation with NSE. The category was subscribed by 96.40 times i.e. for 3,93,32,000 Equity Shares. Total number of shares allotted in this category is 4,08,000 Equity Shares to 42 successful applicants. The category wise details of the Basis of Allotment are as under:

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC	VC'S	TOTAL
ALLOTMENT	-	-	9,000	29,000	2,09,000	1,52,000	9,000	4,08,000

5) Allocation to Market Maker:

The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 128/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed 1.00 times i.e. for 1,08,000 Equity Shares the total number of shares allotted in this category is 1,08,000 Equity Share. The category wise details of the Basis of Allotment are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	1,08,000	1	100.00	1,08,000	100.00	1,08,000	1:1	1,08,000
	TOTAL	**1**	**100.00**	1,08,000	**100.00**	1,08,000		1,08,000

6) Allotment to Anchor Investors (After Technical Rejection)

The Company in consultation with the BRLM has allocated 6,09,000 Equity Shares to 6 Anchor Investors at the Anchor Investor Issue Price of ₹ 128/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC	OTHERS	TOTAL
ALLOTMENT	-	-	-	79,000	4,45,000	85,000	-	6,09,000

The Board of Directors of our Company at its meeting held on November 12, 2025 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being National Stock Exchange of India Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBS have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before November 13, 2025 and In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before November 13, 2025 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from National Stock Exchange of India Limited and the trading of the Equity Shares is expected to commence on November 14, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated November 11, 2025 ("Prospectus").

NOTICE TO INVESTORS: CORRIGENDUM TO THE PROSPECTUS ("THE CORRIGENDUM")

With reference to the Prospectus dated November 11, 2025, filed with the RoC and submitted to the Stock Exchange and SEBI, attention to the investors is drawn to the following:

In furtherance to the disclosure made in the Number of Locked in shares (XII) appearing under the heading "Table I - Summary Statement holding of specified securities" in the chapter titled "Capital Structure" on page no. 78 of the Prospectus shall stand replaced as below:

Category (I)	Category of shareholder(II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV)+(V)+(VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a % of (A+B+C2)	Number of Voting Fresh held in each class of securities (IX)				No of shares underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full convertible securities (as a percentage of diluted share capital) (XI)= (VII)+(X) As a % of (A+B+C2)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)
								No of Voting (XIV) Rights			Total as a % of (A+B+C)			No (a)	As a % of total Shares held (b)	No (a)	As a % of total Shares held (b)	
								Class Equity	Class	Total								
A	Promoters & Promoters Group	7	55,00,000	0	0	55,00,000	92.68	55,00,000	0	55,00,000	92.68	0	0	55,00,000	92.68	0	0	55,00,000
B	Public	29	4,34,434	0	0	4,34,434	7.32	4,34,434	0	4,34,434	7.32	0	0	4,34,434	7.32	0	0	4,34,434
C	Non Promoters Non-Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C1	Shares underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C2	Shares held by Employee Trusts	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Total (A+B+C)	**36**	**59,34,434**	-	-	**59,34,434**	**100.00**	**59,34,434**	-	**59,34,434**	**100.00**	-	**100.00**	**59,34,434**	**100.00**	-	-	**59,34,434**

The Prospectus shall be read in conjunction with this Corrigendum. The information in this Corrigendum supersedes the information provided in the Prospectus to the extent inconsistent with the information in the Prospectus. The Prospectus stands amended to the extent stated hereinabove. All capitalised terms used in this Corrigendum shall unless the context otherwise requires, have the same meanings as ascribed in the Prospectus.

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, MUFG INTIME INDIA PRIVATE LIMITED (Formerly Link Intime India Private Limited) at www.in.mpms.mufg.com

All future correspondence in this regards may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodge and payment details at the address of the Registrar given below:

MUFG INTIME INDIA PRIVATE LIMITED
(Formerly Link Intime India Private Limited)
Address: C- 101, Embassy 247, L B S Marg, Vikhroli West, Mumbai -400083, Maharashtra;
Tel No.: +91 810 811 4949
Email Id: curislifesciences.smeipo@in.mpms.mufg.com
Investor Grievance Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: www.in.mpms.mufg.com **Contact Person:** Ms. Shanti Gopalkrishnan;
SEBI Registration No.: INR000004058; **CIN:** U67190MH1999PTC118368.

On behalf of Board of Directors
FOR, CURIS LIFESCIENCES LIMITED
Sd/-
Nikhil Purohit
Company Secretary & Compliance Officer

Place: Sanand, Gujarat
Date: November 13, 2025

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF CURIS LIFESCIENCES LIMITED

Disclaimer: Curis Lifesciences Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public Issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad on November 11, 2025 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme_offer and is available on the websites of the BRLM at www.finaxcapital.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the chapter titled "Risk Factors" beginning on page 25 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

Alpine

ALPINE HOUSING DEVELOPMENT CORPORATION LIMITED
CIN : L65110KA1992PLC013174
Regd off: 302, Alpine Arch, No. 10, Langford Road, Bangalore 560 027, Karnataka, INDIA
WWW.alpinehousing.com, e-mail: contact@alpinehousing.com Fax:91-80-22128357, Tel:+91-80-40473500
Extract of the un audited Financial Results for the quarter ended 30 September, 2025

Rs in lakhs except EPS

Sl	Particulars	Quarter ended			Half year Ended		Year ended
		30.09.2025 Unaudited	30.09.2024 Unaudited	30.06.2025 Un audited	30.09.2025 Unaudited	30.09.2024 Unaudited	31-03-2025 audited
1	Total Income from Operation(Net)	1527.60	994.50	1732.72	3260.32	2151.90	5919.47
2	Net profit for the period(before Exceptional and Extraordinary items and tax)	86.52	64.66	51.60	138.13	119.29	626.7
3	Net profit for the period before Tax (after exceptional and extraordinary items)	86.52	64.66	51.59	138.12	119.18	616.68
4	Net profit for the period after tax (after Exceptional and extraordinary items)	68.77	52.41	53.73	122.50	101.10	506.29
5	Total comprehensive income for the period (comprising profit for the period(after tax) and other comprehensive income (after tax)	68.77	52.41	53.73	122.50	101.10	506.29
6	Equity Share Capital	1732.1898	1732.1898	1732.1898	1732.1898	1732.1898	1732.1898
7	Other equity	6747.10	6219.61				6624.60
8	Earnings per share(Rs. 10/- each)						
	a) Basic	0.40	0.30	0.31	0.71	0.58	2.92
	b) Diluted	0.40	0.30	0.31	0.71	0.58	2.92

NOTES:
The above is an extract of the detailed format of Unaudited Financial results for the quarter ended 30 September 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 The full format of the Unaudited Financial Results for the quarter ended 30 September, 2025 are available on the Company's website www.alpinehousing.com and the Stock exchange website www.bseindia.com
2. The results have been prepared in accordance with IND AS prescribed under section 133 of the Companies Act 2013

For and on behalf of the Board of Directors
Alpine Housing Development Corporation limited
Sd
SAKabeer
Chairman and Managing Director
DIN 01664782

Place : Bangalore
Date : 13 November, 2025

RACE ECO CHAIN LIMITED

Registered Office: Shop No. 37, Shanker Market, New Delhi, Central Delhi-110001
Website: www.raceecochain.com, Email: contactus@raceecochain.com, CIN : L37100DL1999PLC102506

Extract of Unaudited Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2025
(Amount in Lakhs)

S. No.	Particulars	Quarter Ended 30.09.2025 Unaudited	Quarter Ended 30.09.2024 Unaudited	Half Year Ended 30.09.2025 Unaudited	Financial Year Ended 31.03.2025 Audited
1	*Total income from operations*	14,843.03	10,628.99	30,515.63	55,509.54
2	*Net Profit/ (Loss) for the period (before tax, Exceptional and/or Extraordinary items)*	155.19	77.11	294.65	546.40
3	*Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)*	287.03	77.11	422.25	554.58
4	*Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)*	295.64	-26.03	337.99	419.47
5	*Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]*	-44.36	403.48	151.34	316.08
6	*Paid up Equity Share Capital (Face Value ₹ 10/-)*	1,725.72	1,725.72	1,725.72	1,725.72
7	*Other Equity*	-	-	-	-
8	*Earning Per Share (of Rs.10/- each) (for continuing and discontinued operations)*				
	Basic	1.72	-0.15	1.96	2.49
	Diluted	1.72	-0.15	1.96	2.45

Note: 1) The above is an extract of the detailed format of result for Quarter and half year ended on September 30th, 2025 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said results are available on the website of BSE at **www.bseindia.com**, NSE **www.nseindia.com** as well as on the Company's website at **www.raceecochain.com**.

2) The Key information of Standalone Financial Results for Quarter and Half Year ended on 30th September, 2025 are given below:-

S. No.	Particulars	Quarter Ended 30.09.2025	Quarter Ended 30.09.2024	Half Year Ended 30.09.2025	Financial Year Ended 31.03.2025
1	*Turnover*	9,610.78	10,628.99	19,492.16	46,029.91
2	*Profit before tax*	89.76	78.64	158.66	476.33
3	*Profit after tax*	115.41	-24.50	125.85	375.76

Place: Ghaziabad-UP
Date: November 12th, 2025

By order of the Board
For Race Eco Chain Limited
Sd/-
Sunil Kumar Malik
Managing Director & Chairman
DIN : 00143453

LATTEYS
Non Stop Watering

LATTEYS INDUSTRIES LTD

(CIN No.: L29120GJ2013PLG074281)
Plot No. 16, Phase 1/2, GIDC Estate, Naroda, Ahmedabad - 382330, Gujarat, India

Extract of Statement of Standalone Unaudited Financial Results for the quarter ended September 30, 2025

(Amount in Lakh Rupees)

Sr. No.	Particulars	STANDALONE			
		Quarter Year Ended			Year Ended
		30th Sept 2025	30th June 2025	30th Sept 2024	31st March 2025
		Un-audited	Un-audited	Un-audited	Audited
1.	Total Revenue from Operations	2049.01	2359.59	1873.46	8058.86
2.	Profit before exceptional and extraordinary items and tax	75.85	90.07	93.86	256.35
3.	Profit before Tax	75.85	90.07	93.86	256.32
4.	Profit for the period	57.91	65.60	70.18	180.86
5.	Total Comprehensive Income	58.85	66.54	70.18	184.61
6.	Paid up Equity Share Capital (Equity Shares of Rs. 2/- each)	1149.92	1149.92	1149.92	1149.92
7.	Other Equity excluding Revaluation Reserve	0.00	0.00	0.00	879.01
8.	Earning Per Share				
	Basic:	0.10	0.11	0.12	0.31
	Diluted:	0.10	0.11	0.12	0.31

The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 13, 2025

Additional Information related to ended September 30, 2025: Consolidated

(Amount in Lakh Rupees)

Sr. No.	Particulars	CONSOLIDATED			
		Quarter Year Ended			Year Ended
		30th Sept 2025	30th June 2025	30th Sept 2024	31st March 2025
1.	Total Revenue from Operations	2049.01	2359.59	1873.46	8058.86
2.	Profit before exceptional and extraordinary items and tax	75.82	90.04	93.86	256.35
3.	Profit before Tax	75.82	90.04	93.86	256.32
4.	Profit for the period	57.88	65.57	70.12	180.86
5.	Total Comprehensive Income	58.82	66.51	70.12	184.61
6.	Paid up Equity Share Capital (Equity Shares of Rs. 2/- each)	1149.92	1149.92	1149.92	1149.92
7.	Other Equity excluding Revaluation Reserve		0.00	0.00	879.01
8.	Earning Per Share				
	Basic:	0.10	0.11	0.12	0.31
	Diluted:	0.10	0.11	0.12	0.31

Note:
The above is an extract of the detailed format of unaudited Consolidated Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited Quarterly Financial Results (Consolidated and Standalone) are available on Company's website- www.latteysindustries.com and also on the website of the stock exchange i.e. NSE Limited– www.nseindia.com.

For, Latteys Industries Limited
SD/-
Sonika Jain
Company Secretary & Compliance Officer

Place : Ahmedabad
Date : 13.11.2025

THE INDOGULF GROUP

INDOGULF CROPSCIENCES LIMITED

CIN: L74899DL1993PLC051854
Regd. Office : 501, Gopal Heights, Netaji Subhash Place, Delhi - 110034 (INDIA)
Website: www.groupindogulf.com; **Email:** info@groupindogulf.com

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEP 2025

(₹ in Millions, unless otherwise stated)

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Quarter ended
		30th Sep, 2025	30th June, 2025	30th Sep, 2024	30th Sep, 2025	30th Sep, 2024	31st March, 2025	30th Sep, 2025	30th June, 2025	30th Sep, 2024	30th Sep, 2025	30th Sep, 2024	31st March, 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Total Income	2,484.39	1,861.69	2,399.96	4,346.08	3,725.80	5,966.76	2,502.98	1,903.05	2,338.91	4,406.03	3,664.38	5,944.75
2	Net profit before tax	254.58	36.11	232.28	290.69	254.43	453.41	271.16	46.49	227.38	317.65	247.79	445.70
3	Net profit after tax	194.55	29.54	173.20	224.09	186.94	320.85	206.85	38.67	166.71	245.52	180.18	314.72
4	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	194.94	29.93	173.56	224.87	187.79	322.40	207.24	39.06	167.19	246.30	181.15	316.27
5	Paid-up equity share capital (Face Value ₹ 10/- each)	632.24	487.87	487.87	632.24	487.87	487.87	632.24	487.87	487.87	632.24	487.87	487.87
6	Other equity excluding revaluation reserves	1,453.63	2,304.99	2,140.47	3,758.62	2,140.47	2,275.06	3,769.88	2,303.96	168.69	3,769.88	2,131.27	2,264.90
7	Earnings Per Share(of ₹ 10/- each) in ₹ (not annualised)							1.73	0.80	4.07	2.05	4.40	7.02
	Basic	1.62	0.61	4.23	1.87	4.56	7.16	1.73	0.80	4.07	2.05	4.40	7.02
	Diluted	1.62	0.61	4.23	1.87	4.56	7.16						

Notes:

1 The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the Stock Exchange websites. (www.bseindia.com and www.nseindia.com) and on company's website (www.groupindogulf.com).

2 The above financial results have been reviewed and recommended by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on 12 Nov 2025

3 The Limited Review required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been completed by the auditors of the Company.

For and on Behalf of Board of Directors of
Indogulf Cropsciences Limited

Sanjay Aggarwal
(Managing Director)

Place: DELHI
Date: 12th November, 2025

CONCEPT